Qiming Weekly | Qiming Venture Partners Portfolio News and Updates Vol. 45, 2025
Following the milestones of Qiming Venture Partners' portfolio companies, together with you.
Editor's Note: The "Qiming Weekly" column publishes regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Funding News
01/
Noitom Robotics Completes Pre-A+ Round
Noitom Robotics recently announced the completion of its Pre-A+ round, led by Qiming Venture Partners. Following its Pre-A round and this latest financing, Noitom Robotics has raised a cumulative total of several hundred million RMB.
The proceeds will primarily fund continued R&D investment in multimodal data collection, processing, and delivery capabilities for Embodied Artificial Intelligence; accelerate the build-out of scalable data production systems and engineering platforms; and further strengthen core technical and engineering team capabilities to enhance productized delivery and service capacity — laying a solid foundation for Noitom Robotics' long-term global development.
On this funding round, Dr. Ruoli Dai, founder of Noitom Robotics and a veteran technical expert in motion capture and human-computer interaction, said: "This represents not just validation of our technical direction, but a vote of confidence in long-termism. We're grateful to our investors for trusting a 'robotics company that doesn't build robots.' We'll repay that trust through sustained technical investment and product and service capabilities."
Alex Zhou, Managing Partner at Qiming Venture Partners, said: "As Embodied Artificial Intelligence model algorithms gradually converge and the Scaling Law receives preliminary validation, the ability to acquire high-quality, scalable training data has become a core element in driving the next leap in robotic intelligence. The Noitom Robotics team is one of the very few players in the industry with full-stack data capabilities, with over a decade of technical accumulation. Their entry at this moment, as Embodied Artificial Intelligence enters a period of accelerated development, is precisely timed — riding the momentum upward."
02/
Galaxy Universal Raises $300 Million in New Funding Round
Galaxy Universal, a Qiming Venture Partners portfolio company, recently announced the completion of a new funding round exceeding $300 million, once again setting a record for single-round financing in Embodied Artificial Intelligence. The capital structure and scale of this round demonstrate that the global humanoid robotics industry, after rapid advances in locomotion capabilities, is now entering a new phase of scaled productive force represented by Galaxy Universal.
Following the financing, the company will continue to increase investment in core technologies, accelerate the scaled deployment and iteration of solutions across various domains, deepen industrial synergies with strategic investors, and actively expand its global partnership network — consolidating its leading position as a Chinese Embodied Artificial Intelligence frontrunner and driving the transformation of Embodied Artificial Intelligence technology into a new quality productive force that advances industry.
As the first Embodied Artificial Intelligence enterprise worldwide to truly achieve full-stack self-research spanning "billion-scale high-quality datasets" to "Embodied Foundation Models" to "robot hardware," Galaxy Universal continues to achieve breakthroughs at the technological frontier. Its self-developed Embodied Artificial Intelligence foundation model and other key technologies have achieved multiple global firsts in multi-task generalized manipulation, full-body motion control for humanoid robots, cross-platform autonomous navigation, and dexterous hand fine manipulation — laying a solid technical foundation for the scaled, high-reliability deployment of humanoid robots. Closely aligned with real industrial needs, Galaxy Universal remains committed to building industrial-grade humanoid robots and has already developed mature solutions achieving scaled commercial deployment in industrial manufacturing, instant retail warehousing, smart city services, and healthcare and wellness.
03/
OCUL Completes Series B Round
Recently, Shenzhen-based OCUL Biopharmaceutical Co., Ltd. ("OCUL"), a company focused on innovative ophthalmic drug R&D, successfully completed a $30 million Series B round co-led by Qiming Venture Partners. The proceeds will fully support the Phase II clinical trials in both China and the US for its core product — OCUL101, a first-in-class bispecific antibody ophthalmic drug — injecting strong momentum into the accelerated development of this blockbuster candidate.
Retinal diseases have become a leading cause of irreversible vision impairment worldwide. Neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and geographic atrophy (GA) — three major conditions — afflict tens of millions of patients globally, with urgent unmet clinical needs.
OCUL101, OCUL's self-developed innovative bispecific antibody, targets all three indications as a global first-in-class therapy. Its unique anti-VEGF–complement C5 dual-target design simultaneously blocks three pathological pathways: angiogenesis, vascular leakage, and inflammatory response, fundamentally overcoming the therapeutic limitations of single-target drugs. It is expected to become the first domestic drug for GA and the first globally to cover all three indications, offering patients a more comprehensive treatment option.
04/
Sonosilicon Completes Pre-A Round
Recently, Qiming Venture Partners portfolio company Sonosilicon completed its Pre-A round. Specializing in miniature on-chip ultrasound modules and systems, Sonosilicon builds an autonomous technology chain spanning chips, modules, and intelligent systems, powered by planar array ASICs, silicon-based ultrasound transducers, and edge-computing-based ultrasound AI.
As the only domestic innovator with self-developed 4D planar array ultrasound imaging chips and one of the few globally with an on-chip ultrasound closed-loop system, Sonosilicon continues to drive the localization of high-end ultrasound equipment, filling domestic industrial gaps in large-scale planar array ultrasound, 4D intracardiac echocardiography (4D-ICE), and miniature ring-array intravascular ultrasound (R-IVUS). Through its proprietary eMUTrix™ active planar array ultrasound and flexible interconnect technology, the company is actively pioneering wearable ultrasound patches and ultrasound brain-computer interfaces, providing next-generation life health monitoring and medical diagnostic solutions globally.
Major Partnerships
01/
Biren Technology Partners with Hunan Mobile to Build Domestic Computing Resource Pool
Recently, the Hunan Mobile domestic computing resource pool, jointly built by Hunan Mobile, Qiming Venture Partners portfolio company Biren Technology, and ZTE, was fully completed and successfully powered on. As a key project in China Mobile's national integrated computing system layout, focused on domestic autonomous and controllable capabilities and strengthening intelligent computing infrastructure, this resource pool achieves full domestic self-development from hardware equipment to software systems, fully ensuring national information security and technical autonomy in computing resources. With total computing power reaching the thousand-card scale, the resource pool provides efficient, stable, and secure computing support for Hunan's advantaged industries such as intelligent manufacturing and smart cities, as well as cutting-edge R&D and application deployment — truly enabling "one-point access, full-domain response."
This domestically developed computing resource pool brings together leading forces across the industrial chain. Leveraging its deep technical accumulation in intelligent computing, Biren Technology provides a powerful, stable, and efficient computing foundation for the resource pool; ZTE, as a leading ICT enterprise, ensures stable and efficient operation through advanced intelligent computing network technology; and Hunan Mobile fully utilizes its resource advantages to provide advanced and reliable AIDC infrastructure support. The resource pool's core computing power and stability performance reach industry-leading levels: Biren Technology's high-performance domestic GPUs deliver strong power for large model training and inference; the thousand-card cluster achieves average checkpoint recovery time of less than five minutes, ensuring efficient and stable operation of large-scale computing tasks; and full-stack services from IaaS, PaaS to MaaS and SaaS are provided to facilitate large model innovation and deployment.
02/
Yunji Technology Reaches Strategic Partnership with Thailand's AERO Group
Recently, Qiming Venture Partners portfolio company Yunji Technology reached a formal strategic partnership with AERO Group, a leading Thai enterprise in fluid power and automation. Yunji Technology CEO Quanyin Li and Yang Zi, head of Southeast Asia operations, visited AERO Group's headquarters and factory at the invitation of their hosts, conducting on-site inspections of AERO's system integration and service capabilities in hydraulics, automation, and energy. The two parties signed a cooperation agreement on-site. Under the agreement, AERO Group will become Yunji Technology's exclusive distribution partner in Southeast Asia's industrial sector, marking a significant step forward in Yunji Technology's globalization strategy in a key market.
Going forward, Yunji Technology will export its mature robotics technology products and global deployment experience, while AERO Group will contribute local channel resources, precise scenario insights, and full-process service support — forming a complementary "technology going global + local deep cultivation" collaboration model that precisely addresses core demands in the Southeast Asian market.
03/
Jacobio Pharma and AstraZeneca Reach Global Exclusive Licensing Agreement for Pan-KRAS Inhibitor JAB-23E73
Qiming Venture Partners portfolio company Jacobio Pharma (01167.HK) announced that it has entered into a partnership agreement with AstraZeneca for its self-developed Pan-KRAS inhibitor JAB-23E73. Under the agreement, AstraZeneca will obtain exclusive development and commercialization rights for the product in markets outside China. In the China market, Jacobio will co-develop and co-commercialize the product with AstraZeneca.
Per the agreement terms, Jacobio will receive a $100 million upfront payment and be eligible for additional development and commercialization milestone payments of up to $1.915 billion, as well as tiered royalties on net sales achieved in markets outside China. AstraZeneca will be responsible for all clinical development, regulatory filings, and commercialization activities for JAB-23E73 in markets outside China.
Dr. Yinxiang Wang, Chairman and CEO of Jacobio Pharma: "We are delighted to initiate this collaboration with AstraZeneca. This partnership marks our commitment to bringing world-class R&D programs to the global stage and maximizing the value of our innovative achievements. We are dedicated to providing breakthrough treatment options for patients worldwide, including those with KRAS-mutant tumors, and improving patient survival outcomes."
Matt Hellmann, Senior Vice President, Early Oncology and Precision Medicine, Oncology R&D, AstraZeneca: "KRAS is one of the most important oncogenes in cancer, and tumors carrying KRAS mutations create significant, unmet medical needs among patients with pancreatic, colorectal, and lung cancers. By advancing the development of KRAS inhibitors such as JAB-23E73, and combining this with our diverse oncology portfolio, we are committed to accelerating the development of new therapies with the potential to transform patient outcomes."
Biren Technology, StepFun, and Shanghai Yidian AI Computing Service Reach Strategic Partnership
Qiming Venture Partners portfolio companies Biren Technology, StepFun, and Shanghai Yidian AI Computing Service formally signed a strategic cooperation agreement. This partnership will further enable the three companies to leverage their complementary strengths, continuously explore technological innovation and model breakthroughs, and build a domestic, autonomous, and controllable industrial closed loop from underlying hardware to upper-layer applications — contributing solid momentum to the prosperity of Shanghai's and the nation's AI ecosystem and the secure development of the digital economy.
As a leading domestic provider of general-purpose intelligent computing solutions, Biren Technology focuses on developing domestic general-purpose GPUs, using high-performance domestic chips to fortify the hardware foundation for computing power. StepFun concentrates on foundational large model innovation, providing core algorithmic support for industry applications. Shanghai Yidian AI Computing Service leverages its advantages as the "chain master" enterprise of Shanghai's public computing power service platform, building an efficient and inclusive intelligent computing cloud infrastructure. This agreement facilitates deep complementarity among the three parties' respective strengths in "chip R&D — large model innovation — computing power services," substantially enhancing industrial translation and application efficiency.
Wen Zhang, founder, Chairman and CEO of Biren Technology; Mao Chen, Party Secretary and Chairman of Shanghai Yidian; and Daxin Jiang, founder and CEO of StepFun, jointly witnessed the signing. Wei Ming, Senior Vice President of Strategic Planning at Biren Technology; Liu Shanquan, Vice President of Shanghai Yidian Group and Chairman of Shanghai Aidi Technology Service; and Cao Zhimin, Co-founder and COO of StepFun, signed the agreement on behalf of the three parties.
Product Launches
01/
Shengshu Technology Officially Launches "Professional Video Creation Partner" Vidu Agent
Recently, Qiming Venture Partners portfolio company Shengshu Technology launched Vidu Agent, positioned as a "professional video creation partner" and aiming to become a productivity tool for advertising, e-commerce, and other clients. Users need not become prompt engineering experts, need not learn to build complex workflow nodes, need not switch between multiple platforms, need not splice together multiple storyboards, and need not laboriously deconstruct viral scripts. One product image + one sentence = one-click video generation. One reference video + one image + one sentence = viral video replication.
Vidu Agent is positioned as a commercially viable, one-stop AI video Agent solution, truly achieving "simple operations, professional-grade output." 1. One-stop creative output: No need to switch between multiple platforms; generate professional-grade content in one place, combining imagination × storyboard-level controllability × refined editing capability. 2. High efficiency and cost-effectiveness: Supports one-click video generation, template replication, and batch creation, making creation efficient and simple while substantially lowering the barrier to entry. 3. Diversified scenario customization: From inspiration generation to structured video output, meeting users' varied creative needs with support for multiple languages and scenarios.
02/
Tashi Zhihang's Full-Stack Technology Makes Its Debut with "Embroidery"
Recently, Qiming Venture Partners portfolio company Tashi Zhihang successfully concluded its "TA Is Here: Needle Mastery" technology debut livestream. During this broadcast, the world's first robot capable of autonomous embroidery was officially unveiled, demonstrating the coupling of technology and innovation through sub-millimeter precision operations.
When the "needle mastery" of fingertip embroidery gains the "real strength" to migrate to industrial scenarios, Tashi Zhihang breaks through flexible precision manufacturing and conquers wire harnesses — the "Goldbach conjecture" of industrial automation. This is not merely success in a single scenario; it provides a verifiable, replicable industrial-grade practical sample for the industrial implementation of Embodied AI's Scaling Law.
At the livestream event, Tashi Zhihang showcased the world's first robot to complete hand embroidery. Through fine control of the needle, the complex and precise embroidery process accomplished smooth thread pulling, needle placement, and piercing actions, ultimately producing the Tashi Zhihang logo — fully demonstrating breakthrough capabilities in flexible material manipulation and极限操作精度.
This was no simple embroidery demonstration, but rather a "hexagonal capability verification" of a fine, complex, long-horizon operational task. The demonstration集中体现了多项核心能力: sub-millimeter ultra-high precision, flexible and coordinated bimanual collaboration, precise response to the properties of flexible objects, delicate force-touch control capabilities, and high success-rate execution in complex long-horizon tasks.
Beyond the embroidery demonstration, Tashi Zhihang further showcased the real-world deployment capabilities of flexible precision manipulation technology in industrial scenarios, becoming the world's first company to solve the wire harness manufacturing challenge in robotics. Thereby, Tashi Zhihang successfully transcended the capability boundaries of traditional industrial robots in complex flexible tasks, achieving autonomous wire harness assembly operations and providing an entirely new technical path and practical paradigm for intelligent upgrading in high-end manufacturing industries.
03/
Unisound Releases Medical Domain Expert Large Model "Shanhai · Zhiyi Medical Model 5.0"
Recently, Qiming Venture Partners portfolio company Unisound officially launched its latest medical domain expert-grade large model — "Shanhai · Zhiyi Medical Model 5.0." This milestone release marks the critical evolution of its medical large model from "intelligent tool" to "clinical collaborator," empowering the full process of serious medical practice with deeper medical understanding, more proactive collaboration capabilities, and more reliable output — opening a new chapter in intelligent healthcare.
As a company that has long been deeply rooted in the medical AI track, Unisound has built substantial expertise in the AI healthcare space. In May 2023, it launched Shanhai, a general-purpose multimodal large model, and on that foundation introduced the same year a specialized medical large model, "Shanhai Zhiyi" (Shanhai Medical Sage), designed to transform a "generalist" into a "specialist" by using the general-purpose model as a base, then applying professional data training, regulatory compliance adaptation, and workflow customization. The goal was to address core pain points in the medical industry while controlling risk and reducing costs, driving AI to truly integrate into the healthcare system and create value.
This release of Shanhai Zhiyi Medical Large Model 5.0 represents the culmination of Unisound's work in the medical field. It is not simply a parameter update, but a systematic reshaping of capabilities built around real clinical needs. Powered by a dual-core engine of "medical text large model + medical multimodal large model," it achieves deep evolution across four core capabilities, constructing the most comprehensively capable medical AI support system in the industry and adapting to clinical needs on all fronts.
R&D Progress
01/
InventisBio's CSF-1R Inhibitor Bexmab® Receives NMPA Approval
Recently, Qiming Venture Partners portfolio company InventisBio (02256.HK) announced that its independently developed CSF-1R highly selective small-molecule inhibitor Bexmab® (pimicotinib hydrochloride capsules) has been approved by China's National Medical Products Administration (NMPA) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection could result in limited function or severe complications. Following approval, Merck Group will work to make this product available to TGCT patients in China as quickly as possible.
Bexmab® is a novel, orally available, highly selective and potent small-molecule CSF-1R inhibitor independently developed by InventisBio. This NMPA approval is based on positive results from the global Phase III MANEUVER study. The study showed that Bexmab® achieved the highest objective response rate (ORR) assessed by RECIST v1.1 criteria to date among all Phase III studies of systemic TGCT treatment. At week 25, as assessed by blinded independent review committee (BIRC) based on RECIST v1.1 criteria, Bexmab® demonstrated statistically significant superiority over placebo in the primary endpoint of ORR (54.0% vs. 3.2%, P<0.0001). Bexmab® also achieved clinically meaningful and statistically significant improvements across multiple key secondary endpoints closely related to patients' quality of life, including improved range of joint motion (p=0.0003), improved physical function (PROMIS-PF; p=0.0074), and reduced worst stiffness (p<0.0001) and worst pain (p<0.0001). Long-term follow-up data presented at the 2025 European Society for Medical Oncology (ESMO) Congress further demonstrated that Bexmab® can deliver robust and durable tumor response in TGCT patients. At a median follow-up of 14.3 months, patients who received Bexmab® from study start showed a significant improvement in ORR from 54% at week 25 to 76.2% (95% CI: 63.8, 86.0), including 4 patients who achieved complete response.
Dr. Yaozhong Xu, Founder and CEO of InventisBio, stated: "This approval is not only a regulatory milestone, but a defining moment in InventisBio's development journey. It marks our evolution from pioneers of scientific innovation to a company capable of delivering breakthrough therapies to patients. With an unwavering commitment to addressing real clinical needs, we will continue to advance the development of breakthrough and differentiated medicines, with the aim of reshaping the treatment landscape for cancer and other diseases in China and globally. As the first independently developed CSF-1R inhibitor approved in China, Bexmab® not only fills a critical gap in TGCT treatment, but also validates our determination and capability to practice innovation with a global perspective and translate cutting-edge concepts into clinical value."
02/
Yanshengchao's YSC001 Project Receives IND Approval
Recently, Qiming Venture Partners portfolio company Yanshengchao (Beijing) Biotech announced important R&D progress: its first independently developed innovative drug project, YSC001, has successfully received a new drug clinical trial (IND) approval from the Center for Drug Evaluation, NMPA (CDE).
This marks the successful completion of key validation of preclinical research for the YSC001 project and formal approval to enter the clinical trial phase. It is an important milestone in the company's rapid growth, and a significant step for Yanshengchao in addressing the common pain points of autoimmune and inflammatory diseases — "insufficient drug efficacy, high recurrence rates, and significant side effects" — through innovative drug development.
The novel target addressed by the YSC001 project enables dual clearance of pathogenic T cells and B cells without interfering with the body's large population of naïve T cells and B cells, significantly improving efficacy while reducing post-treatment infection risk. Its unique dual-action mechanism has demonstrated efficacy clearly superior to existing drugs in nearly ten autoimmune disease animal models, and has been validated in the company's proprietary in vitro human cell experimental system.
This IND approval for the YSC001 project also marks the company's efforts to translate cutting-edge scientific discoveries into clinical value entering an entirely new phase. Yanshengchao will fully advance YSC001's clinical trials, systematically evaluating its safety, tolerability, and efficacy. We are confident and hopeful that through rigorous clinical research, we can bring more effective and safer medicines to patients with autoimmune diseases.
03/
Asieris Pharma's APL-2401 Receives NMPA Approval for Phase I Clinical Trial in FGFR2/3-Driven Advanced Solid Tumors
Recently, Qiming Venture Partners portfolio company Asieris Pharma (688176.SH), a global innovative drug company focused on urogenital system tumors and women's health, announced that its independently developed APL-2401 (drug name: ASN-8639 tablets) has received approval from China's National Medical Products Administration (NMPA) to conduct a Phase I clinical trial in patients with FGFR2/3-driven advanced solid tumors. Notably, APL-2401 is a globally co-developed Class 1 innovative drug. Its international multicenter clinical trial design and application materials meet international clinical trial technical standards, and it was successfully included in the "30-Day Channel" established under the NMPA's September 12, 2025 announcement "On Matters Related to Optimizing the Review and Approval of Innovative Drug Clinical Trials (Announcement No. 86 of 2025)," receiving approval in just 22 working days and becoming one of the first projects nationwide to be approved under this new policy.
APL-2401 is a highly selective fibroblast growth factor receptor 2/3 (FGFR2/3) dual-target small-molecule inhibitor independently developed by the company, with the potential to provide a new treatment option for patients with advanced solid tumors (such as urothelial carcinoma, cholangiocarcinoma, endometrial cancer, gastric cancer, breast cancer, ovarian cancer, non-small cell lung cancer, and other specific solid tumors).
Zhang Yun, Chief Medical Officer of Asieris Pharma, stated: "We are very pleased that APL-2401's IND has been approved by the NMPA, and the company will actively advance the clinical development of this product. APL-2401 has already completed clinical trial filing with the Therapeutic Goods Administration (TGA) under Australia's Department of Health. We very much look forward to the clinical data for this candidate drug, to further demonstrate its safety and efficacy, and to benefit more patients in line with actual clinical treatment needs."
04/
EpiGenTek's Epigenetic Therapy EPI-003 Receives FDA Clinical Trial Authorization
Recently, Qiming Venture Partners portfolio company EpiGenTek, a clinical-stage innovative drug R&D company, announced that its innovative epigenetic regulatory therapy EPI-003 has formally received clinical trial authorization (IND) from the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B. EPI-003 is the world's first epigenetic regulatory therapy based on lipid nanoparticle (LNP) delivery technology to receive FDA approval to enter clinical trials. Currently, the drug's Phase I clinical trial is proceeding smoothly in New Zealand, Australia, and Hong Kong. This FDA authorization will strongly advance EPI-003's global multicenter clinical development.
EPI-003 is an intravenous antiviral drug based on a novel mechanism of action. Through an LNP delivery system, the drug precisely delivers mRNA encoding epigenetic regulatory proteins and guide RNA targeting HBV genes to liver cells, directly performing persistent epigenetic modification on cccDNA and integrated DNA, thereby suppressing the generation of all viral products at the transcriptional source. Preclinical studies have shown that EPI-003 can significantly and sustainably reduce hepatitis B surface antigen (HBsAg) and HBV DNA levels, and maintain long-term efficacy after drug discontinuation, demonstrating the potential to achieve functional cure and even complete cure of hepatitis B.
Dr. Baohong Zhang, co-founder and CEO of Epigenic Therapeutics, said: "The FDA's clearance for EPI-003 to enter clinical trials is a critical milestone on its global development path. This is not only the first FDA-approved epigenetic therapy based on LNP delivery, but also represents substantive progress in our efforts to tackle chronic hepatitis B using cutting-edge technology. We will advance clinical studies with full force, with the goal of bringing transformative treatment options to the hundreds of millions of patients worldwide as soon as possible."
Technology Strength
Tigermed Participates in Academic Conference on Atopic Dermatitis
Recently, the "2025 First Xizi Academic Exchange Conference on Atopic Dermatitis," hosted by the Dermatovenereology Committee of the Chinese Association of Integrative Medicine, concluded successfully in Hangzhou. The conference was chaired by Professor Liming Wu, Director of the Department of Dermatology at Hangzhou First People's Hospital, affiliated with Westlake University School of Medicine. Centered on the theme of "Integration of Chinese and Western Medicine," the conference focused on cutting-edge topics in clinical diagnosis, treatment, and scientific research innovation for atopic dermatitis, building an interdisciplinary, high-level academic exchange platform that attracted clinical dermatology experts, researchers, and pharmaceutical industry representatives from across the country to discuss developments in the field. Multiple experts from Qiming Venture Partners portfolio company Tigermed were invited to attend, sharing insights on dermatology clinical research project management, bottlenecks in new drug development, and future breakthroughs.
The successful convening of this Xizi Academic Exchange Conference brought comprehensive, in-depth exchanges on atopic dermatitis (AD) treatment — from strategic discussions on new drug development to practical implementation of clinical research. As a deep participant in dermatology clinical research, Tigermed has contributed to the successful market launch of drugs in multiple subfields including atopic dermatitis, chronic spontaneous urticaria, and alopecia areata, and has cumulatively implemented over 200 clinical trials related to dermatology.
Corporate Honors
01/
Hesai Technology Selected for Morgan Stanley's Humanoid Tech 25
Recently, global lidar industry leader Hesai Technology (NASDAQ: HSAI, 02525.HK) was selected for Morgan Stanley's prestigious "Humanoid Tech 25" list. The list focuses on the 25 most influential robotics and related technology companies globally. Hesai Technology received high recognition for providing critical 3D perception capabilities that enable robots to deploy at scale in the real physical world, becoming the only lidar company worldwide to make the list.
Selected alongside Hesai Technology were benchmark global technology and robotics companies including NVIDIA, AMD, Sony, and Samsung, fully demonstrating Hesai Technology's important position in the global robotics industry chain.
Morgan Stanley's high recognition fully reflects Hesai Technology's comprehensive advantages in core technology, scalable manufacturing capabilities, and broad market deployment. As the report noted: "Building a prototype is not hard; achieving mass production is."
02/
Insilico Medicine Research Selected for Nature Biotechnology's 2025 Top Research Advances
Recently, the Nature Biotechnology editorial team selected the year's key research highlights from work published in Nature Biotechnology and other journals in 2025. This year, the biotechnology field accelerated at the intersection of gene editing, cell and gene therapy, immunotherapy, and artificial intelligence (AI): CRISPR-based editing tools became increasingly precise with significantly enhanced clinical relevance, and biotechnology continues to expand the boundaries of immunotherapy.
Research co-authored by Qiming Venture Partners portfolio company Insilico Medicine, "Quantum-computing-enhanced algorithm unveils potential KRAS inhibitors," was selected for this year's Top 10 Research Advances list and featured on the cover. This also marks the first time a quantum computing achievement in drug discovery has been selected for Nature Biotechnology's annual highlighted articles list.
Previous Highlights
Qiming Weekly | Qiming Venture Partners Portfolio Company Funding and Updates Vol. 44, 2025
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total committed capital reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early- and growth-stage companies in the Technology and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means, with 80+ companies recognized as unicorns or super-unicorns in their respective industries.
Many Qiming Venture Partners portfolio companies have grown into the most influential companies in their fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ: BILI, 09626.HK), Zhihu (NYSE: ZH, 02390.HK), Roborock (688169.SH), Hesai Technology (NASDAQ: HSAI, 02525.HK), UBTECH (09880.HK), WeRide (NASDAQ: WRD, 00800.HK), HyperStrong (688411.SH), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ: ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ: SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Sinocelltech (688520.SH), AusperBio, Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.